Replimune Group, Inc.

NASDAQ:REPL

Biotechnology

Healthcare
$19.81 +1.85%

+$0.19 today

Market cap
$1.88B
Beta
0.91
P/E (TTM)
-3.0
EPS (TTM)
-$3.42
52W Low $1.50High $13.24

Volume 2.13M

Average 7.51M

Returns on capital

Replimune Group, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-59.5%

avg -11.9%

ROIC

-53.1%

avg -33.4%

ROA

-44.9%

avg -29.2%

Analysis

ROA is currently the strongest return metric at -44.9% versus its period average of -29.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Sushil Patel

Chief Executive Officer & DirectorUSD 1.02M55708.15K0.86%

Philip Astley-Sparke

Executive ChairmanUSD 960.52K551.36M1.65%

Konstantinos Xynos

Chief Medical OfficerUSD 748.53K60224.22K0.27%

Emily Luisa Hill

Chief Financial OfficerUSD 728.32K46215.85K0.26%

Michelle DiNapoli

Chief Commercial OfficerUSD 594.58K———

Andrew Schwendenman

Chief Accounting Officer & Treasurer—5099.42K0.12%

Camilo Garcia

Chief Human Resource Officer————

Paul Bullock

Chief Manufacturing Officer & Framingham Site Head————

Shawn Glidden

Chief Legal Officer————

Arleen Goldenberg

Head of Investor Relations————

Kari Jeschke

Senior Vice President of Regulatory Affairs————

Nina Aragam

Chief Operations Officer————

Carolyn Trott

Senior Vice President of Quality Assurance————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 20, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

2

$273.63

Sells

17

$2.34M

Net Transaction Value

−$2.34M

Net selling

Most Active

Hill Emily Luisa

3 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 9, 26

SLATTERY JOSEPH P

Direct

Sell$113.4K
Nov 2, 26

Dhingra Kapil

Direct

Sell$408.5K
Aug 17, 26

Hill Emily Luisa

Direct

Sell$132.2K
Aug 11, 26

BAKER BROS. ADVISORS LP

Indirect

Buy$261
Aug 11, 26

BAKER BROS. ADVISORS LP

Indirect

Buy$12.6
Aug 10, 26

Patel Sushil

Direct

Sell$510.3K
Aug 10, 26

Hill Emily Luisa

Direct

Sell$148.5K
Aug 10, 26

Xynos Konstantinos

Direct

Sell$148.5K
Aug 10, 26

Schwendenman Andrew

Direct

Sell$99K
Jun 1, 26

Sarchi Christopher

Direct

Sell$110.9K

1–10 of 19

Summary

Insiders reported 2 buys worth $273.63 and 17 sells worth $2.34M over the last 12 months. That adds up to net selling of $2.34M. Hill Emily Luisa was the most active insider with 3 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A2 analysts
RevenueN/AN/AN/A
N/A3 analysts
Net IncomeN/AN/AN/A
N/A3 analysts
EBITN/AN/AN/A
N/A3 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Replimune Group, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about REPL's management, answered from reported figures.

Who manages REPL?

Replimune Group, Inc. (REPL) lists 13 active executives. The top listed executive is Konstantinos Xynos, Chief Medical Officer.

Are REPL insiders buying or selling?

Recent insider activity shows net buying of $32.31M.